Drug Approval | February 18, 2023
Themis gets DCGI approval of Remifentanil Hydrochloride 1mg/2mg injection for import and marketing
Themis will market this drug with the brand name REMITHEM.
Themis will market this drug with the brand name REMITHEM.
USFDA has issued an Establishment Inspection Report (EIR) for Piramal Pharma Limited manufacturing facility located at Lexington (Kentucky, USA) and the inspection has now been successfully closed by the USFDA
This registration enables companies to register the products (Orodispersible films and Transdermal systems) in UAE for commercialization
Label expansion for CIBINQO provides new systemic oral option for adolescents (12 to <18 years) with moderate-to-severe atopic dermatitis
Laurus Labs has announced that the USFDA completed inspection of the formulations manufacturing facility Unit-2, APSEZ, Atchutapuram, Visakhapatnam, Andhra Pradesh.
With the recent sales force expansion and new product launches, we expect to be back to above-market growth
The Tc 99m Mertiatide Injection is used in the diagnosis of congenital and acquired renal abnormalities
Zidavi is recommended by the Infectious Disease Society of America
The Durezol brand and generic had US sales of approximately US $40 million MAT for the most recent twelve months ending in Nov 2022 according to IQVIA
Granules now have a total of 53 ANDA approvals from USFDA
Subscribe To Our Newsletter & Stay Updated
